These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 9531525)

  • 1. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
    Zhang Y; Guo X; Lin ET; Benet LZ
    Drug Metab Dispos; 1998 Apr; 26(4):360-6. PubMed ID: 9531525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats.
    Zhang Y; Hsieh Y; Izumi T; Lin ET; Benet LZ
    J Pharmacol Exp Ther; 1998 Oct; 287(1):246-52. PubMed ID: 9765344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
    Wandel C; Kim RB; Guengerich FP; Wood AJ
    Drug Metab Dispos; 2000 Aug; 28(8):895-8. PubMed ID: 10901697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
    Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
    Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.
    Botsch S; Gautier JC; Beaune P; Eichelbaum M; Kroemer HK
    Mol Pharmacol; 1993 Jan; 43(1):120-6. PubMed ID: 8423765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
    J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
    Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
    Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model.
    Cummins CL; Salphati L; Reid MJ; Benet LZ
    J Pharmacol Exp Ther; 2003 Apr; 305(1):306-14. PubMed ID: 12649383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
    Wandel C; Kim RB; Kajiji S; Guengerich P; Wilkinson GR; Wood AJ
    Cancer Res; 1999 Aug; 59(16):3944-8. PubMed ID: 10463589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics.
    Wacher VJ; Silverman JA; Zhang Y; Benet LZ
    J Pharm Sci; 1998 Nov; 87(11):1322-30. PubMed ID: 9811484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
    Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
    Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds.
    Yumoto R; Murakami T; Nakamoto Y; Hasegawa R; Nagai J; Takano M
    J Pharmacol Exp Ther; 1999 Apr; 289(1):149-55. PubMed ID: 10086998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers.
    Zhang Y; Benet LZ
    Pharm Res; 1998 Oct; 15(10):1520-4. PubMed ID: 9794492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro biotransformation of a novel antimalarial cysteine protease inhibitor in human liver microsomes.
    Zhang Y; Guo X; Lin ET; Benet LZ
    Pharmacology; 1999 Mar; 58(3):147-59. PubMed ID: 9925971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-glycoprotein-mediated efflux of indinavir metabolites in Caco-2 cells expressing cytochrome P450 3A4.
    Hochman JH; Chiba M; Yamazaki M; Tang C; Lin JH
    J Pharmacol Exp Ther; 2001 Jul; 298(1):323-30. PubMed ID: 11408558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
    Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes.
    Postlind H; DanielsonA ; Lindgren A; Andersson SH
    Drug Metab Dispos; 1998 Apr; 26(4):289-93. PubMed ID: 9531513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes.
    Ekström G; Gunnarsson UB
    Drug Metab Dispos; 1996 Sep; 24(9):955-61. PubMed ID: 8886604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
    Warrington JS; Poku JW; von Moltke LL; Shader RI; Harmatz JS; Greenblatt DJ
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1024-31. PubMed ID: 10688619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A.
    Voorman RL; Maio SM; Payne NA; Zhao Z; Koeplinger KA; Wang X
    J Pharmacol Exp Ther; 1998 Oct; 287(1):381-8. PubMed ID: 9765359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.